SCHEMBL1639160

SCHEMBL1639160

COc1ccc(O)c(C(=O)NN)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 2/20 0.58
F2 P00734 1/20 0.58
F10 P00742 1/20 0.58
PLAT P00750 1/20 0.58
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
NPC1 O15118 4/20 0.57
RAB9A P51151 4/20 0.57
KDM4E B2RXH2 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
MAPT P10636 3/20 0.57
ALDH1A1 P00352 3/20 0.57
HPGD P15428 3/20 0.57
TP53 P04637 2/20 0.57
ALOX12 P18054 2/20 0.57
HSD17B10 Q99714 2/20 0.57
LMNA P02545 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4932107 0.86 ALDH1A1 (0.66) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL10557566 0.86 CA1 (0.59) KMT2ANPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL17414607 0.84 P2RX1 (0.57) PLAUF2F10PLATMEN1
SCHEMBL1436731 0.84 P2RX1 (0.57) PLAUF2F10PLATMEN1
SCHEMBL6478100 0.83 CTSD (0.62) MEN1KMT2AKDM4ESMN1; SMN2MAPT
SCHEMBL25213585 0.81 CA1 (0.54) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL9778317 0.81 HPGD (0.63) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL8981619 0.81 KDM4E (0.57) PLAUF2F10PLATMEN1
SCHEMBL551750 0.80 NPC1 (0.56) PLAUF2F10PLATMEN1
Methyl 2-Hydroxy-5-Methoxybenzoate SCHEMBL643758 0.80 CA1 (0.72) MEN1KMT2ANPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed
WO-2003103567-A2 NITROSODIPHENYLAMINE DERIVATIVES, COMPOSITIONS COMPRISING THEM, AND THE USE THEREOF AS ANTIOXIDANTS AND SPONTANEOUS NITRIC OXIDE DONORS MERCK PATENT GMBH (DE) 2003-12-18 WO disclosed
US-6080772-A 2-AMINOTHIAZOLE TRIAZOLE OR TETRAZOLE COMPOUND FOR REGULATING PROTEIN TYROSINE PHOSPHATASE ACTIVITY SUGEN, INC. (US) 2000-06-27 US disclosed
WO-1998027092-A1 THIAZOLE COMPOUNDS AND METHODS OF MODULATING SIGNAL TRANSDUCTION SUGEN, INC. (US) 1998-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 PLAU 2008/4885F2 3508/4885F10 3411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.